Taming Metabolic Disease

Jul 15, 2008

Over at In the Pipeline, Derek Lowe wonders what compounds might make good metabolic disease targets, harkening back to one put out there in 2002 by a company called Sumitomo Pharmaceuticals. He sees promise in CAMKK2, in that it's more upstream and involved in numerous pathways for regulation of appetite and glucose levels, including ghrelin, AMPK, and NPY.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Keep It (Partly) Virtual

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

For Cross-Protection

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Proteomics of Severity

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

Genome Biology Papers on Regulatory Element, Single-Cell Integration, Sequence Simulation Tools

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.

Menu